NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

GT Biopharma, Inc. (GTBP) Stock Analysis

GT Biopharma, Inc. (GTBP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GTBP

$5.41

−$1.90 (−25.99%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GTBP with… →

GTBP Key Statistics

As of Oct 21, 2026
Trading
Open
$6.81
Previous Close
$7.31
Day's Range
5.31–6.90
52-Week Range
4.91–28.75
Volume
169.82K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.86
Valuation
Market Cap
$11.15M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.05
EPS (ttm)Profit attributable to each share over the last twelve months.
−147.50
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$28.35M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.06M
1-Year Return
+673.96%
Dividend and dates
Avg Volume
56.00K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GTBP closed at $5.41, +673.96% over 1 year.

GT Biopharma, Inc. (GTBP) has a market capitalization of $11.15M.

In fiscal 2025, GTBP reported revenue of $0.00.

GTBP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+589.17%
2025−74.26%
2024−60.13%
2023−71.22%
2022−70.95%
2021−57.69%
2020+423.46%
2019−87.54%
2018 (partial year)−60.84%

As of October 21, 2026.

GTBP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$28.35M—
2024$0.00−$13.16M—
2023$0.00−$7.60M—
2022$0.00−$20.88M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$12.42M−$28.35M—
2024$0.00—−$14.36M−$13.16M—
2023$0.00—−$13.58M−$7.60M—
2022$0.00—−$21.26M−$20.88M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

GT Biopharma, Inc. (GTBP) is capitalised at $11.15M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 1.

The most recent close on file for GTBP is $5.41, dated October 21, 2026. That is −$1.90 (−25.99%) against the previous close. The 52-week range on file runs from $4.91 to $28.75. The latest close sits 10.18% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $28.35M. Trailing earnings per share are −147.5.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.05.

Over the trailing twelve months the total return is +673.96%. Across 5 years the annualized return works out at −51.37%. The reported beta is 0.86. Daily returns over the trailing 8 years annualize to a volatility of 1,922.35%.

Growth & Income

No dividend is on file for GTBP.

2026 is still running; the total return is +589.17% year to date. Across the complete calendar years on file, 2020 returned +423.46% and 2019 returned −87.54%. Of the 7 complete calendar years on file, 1 finished higher.

Peer Comparison

GT Biopharma, Inc. (GTBP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GT Biopharma, Inc. GTBP $11.15M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. GT Biopharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About GT Biopharma, Inc.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

Visit website →